These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23429865)

  • 1. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study.
    Tsai HT; Marshall JL; Weiss SR; Huang CY; Warren JL; Freedman AN; Fu AZ; Sansbury LB; Potosky AL
    Ann Oncol; 2013 Jun; 24(6):1574-9. PubMed ID: 23429865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study.
    Kozloff MF; Berlin J; Flynn PJ; Kabbinavar F; Ashby M; Dong W; Sing AP; Grothey A
    Oncology; 2010; 78(5-6):329-39. PubMed ID: 20733336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.
    Naeim A; Ward PR; Wang HJ; Dichmann R; Liem AK; Chan D; Patel R; Hu EH; Tchekmedyian NS; Wainberg ZA; Hecht JR
    J Geriatr Oncol; 2013 Oct; 4(4):302-9. PubMed ID: 24472472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of bevacizumab in US elderly patients with colorectal cancer receiving chemotherapy.
    Fu AZ; Tsai HT; Marshall JL; Freedman AN; Potosky AL
    J Oncol Pharm Pract; 2014 Oct; 20(5):332-40. PubMed ID: 24122849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.
    Grothey A; Flick ED; Cohn AL; Bekaii-Saab TS; Bendell JC; Kozloff M; Roach N; Mun Y; Fish S; Hurwitz HI
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):726-34. PubMed ID: 24830357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.
    Tebbutt NC; Murphy F; Zannino D; Wilson K; Cummins MM; Abdi E; Strickland AH; Lowenthal RM; Marx G; Karapetis C; Shannon J; Goldstein D; Nayagam SS; Blum R; Chantrill L; Simes RJ; Price TJ;
    Ann Oncol; 2011 Aug; 22(8):1834-8. PubMed ID: 21273347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer.
    Yoshioka Y; Uehara K; Ebata T; Yokoyama Y; Mitsuma A; Ando Y; Nagino M
    Surg Today; 2014 Jul; 44(7):1300-6. PubMed ID: 23942819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients.
    Petrelli F; Coinu A; Cabiddu M; Borgonovo K; Lonati V; Ghilardi M; Barni S
    Med Oncol; 2015 Feb; 32(2):456. PubMed ID: 25572811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab in elderly patients with metastatic colorectal cancer.
    Sclafani F; Cunningham D
    J Geriatr Oncol; 2014 Jan; 5(1):78-88. PubMed ID: 24484722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases.
    Li DB; Ye F; Wu XR; Wu LP; Chen JX; Li B; Zhou YM
    World J Gastroenterol; 2013 Feb; 19(5):761-8. PubMed ID: 23431050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.
    Hurwitz HI; Bekaii-Saab TS; Bendell JC; Cohn AL; Kozloff M; Roach N; Mun Y; Fish S; Flick ED; Grothey A;
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):323-32. PubMed ID: 24686090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
    Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.
    Kabbinavar FF; Flynn PJ; Kozloff M; Ashby MA; Sing A; Barr CE; Grothey A
    Eur J Cancer; 2012 May; 48(8):1126-32. PubMed ID: 22424880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
    Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients.
    Millet G; Truant S; Leteurtre E; Hebbar M; Zerbib P; Huet G; Boleslawski E; Pruvot FR
    Ann Surg; 2012 Nov; 256(5):755-61; discussion 761-2. PubMed ID: 23095619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
    Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
    Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
    Duran AO; Karaca H; Besiroglu M; Bayoglu IV; Menekse S; Yapici HS; Yazilitas D; Bahceci A; Uysal M; Sevinc A; Hacibekiroglu I; Aksoy A; Tanriverdi O; Arpaci E; Inanc M; Dane F; Ozkan M
    Asian Pac J Cancer Prev; 2014; 15(23):10375-9. PubMed ID: 25556478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.